ADVERTISEMENT
Natco Pharma Q2 Results Review - Earnings Below Estimates: Dolat Capital
Decline in earnings was due to minimal profit share associated with gRevlimid sales in the U.S., which was majorly booked in Q1.
12 Nov 2022, 04:18 PM IST 
API manufacturing facility at Natco Pharma Ltd. (Source: Company website)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
I’m already a Subscriber Sign In
To continue reading this storySubscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Minimal Ad
Experience
Members-Only
Rewards
Still Not convinced ? Know More
